No immediate trading implications. Monitor for future Form 4 filings to see if Greene acquires or disposes of shares.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 24 $20.33entry
- T+1 · 5mo ago +1.38%α +1.23% · $20.61
- T+5 · 5mo ago +7.18%α +5.47% · $21.79
- T+20 · 4mo ago +14.17%α +12.23% · $23.21
- T+60 · 2mo ago −11.17%α −15.17% · $18.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Barry Greene filed an initial beneficial ownership statement (Form 3) with the SEC, indicating he has become an officer, director, or 10% shareholder of Dyne Therapeutics. The filing includes a standard limited power of attorney for Section 16 reporting. No transactions or holdings were disclosed.
Key Facts
- Form 3 filed by Barry Greene on June 22, 2026
- Powers of attorney granted for Section 16 filings
- No securities transactions or holdings reported in this filing
Financial Impact
No financial impact; routine administrative filing.
Risk Factors
- None from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001291963-26-000007 |
| Document: 0001291963-26-000007-index-headers.html | 0001291963-26-000007 |
| Document: 0001291963-26-000007-index.html | 0001291963-26-000007 |
| Document: 0001291963-26-000007.txt | 0001291963-26-000007 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers